Positron Emission Tomography/Computed Tomography–Based Assessments of Androgen Receptor Expression and Glycolytic Activity as a Prognostic Biomarker for Metastatic Castration-Resistant Prostate Cancer
Open Access
- 1 February 2018
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA Oncology
- Vol. 4 (2), 217-224
- https://doi.org/10.1001/jamaoncol.2017.3588
Abstract
An estimated 26 730 men in the United States will die from prostate cancer in 2017.1 The lethal form of the disease generally occurs when prostate cancer reaches a state of castration resistance and widely metastasizes. The androgen receptor (AR) axis remains functional in this advanced state by several mechanisms, including mutation, overexpression, and ligand-independent activation.2 Effective new drugs that target the AR-signaling axis are in development. Two such agents, abiraterone acetate and enzalutamide, have been approved for treating advanced prostate cancer based on demonstration of improved survival.3-6This publication has 19 references indexed in Scilit:
- Enzalutamide in Metastatic Prostate Cancer before ChemotherapyThe New England Journal of Medicine, 2014
- Updated Prognostic Model for Predicting Overall Survival in First-Line Chemotherapy for Patients With Metastatic Castration-Resistant Prostate CancerJournal of Clinical Oncology, 2014
- Cancer statistics, 2014CA: A Cancer Journal for Clinicians, 2014
- Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 studyThe Lancet Oncology, 2012
- Increased Survival with Enzalutamide in Prostate Cancer after ChemotherapyThe New England Journal of Medicine, 2012
- Practical Approach for Comparative Analysis of Multilesion Molecular Imaging Using a Semiautomated Program for PET/CTJournal of Nuclear Medicine, 2011
- End Points and Outcomes in Castration-Resistant Prostate Cancer: From Clinical Trials to Clinical PracticeJournal of Clinical Oncology, 2011
- Abiraterone and Increased Survival in Metastatic Prostate CancerThe New England Journal of Medicine, 2011
- Nodal Staging Score: A Tool to Assess Adequate Staging of Node-Negative Colon CancerJournal of Clinical Oncology, 2009
- Targeting the androgen receptor pathway in prostate cancerCurrent Opinion in Pharmacology, 2008